Transformed cutaneous T cell lymphoma and biclonal gammopathy. 1996

E S Miralles, and M Núñez, and P Boixeda, and R Moreno, and C Bellas, and A Ledo
Servicio de Dermatologiá, Universidad Alcalá de Henares, Hospital Ramón y Cajal, Madrid, Spain.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009182 Mycosis Fungoides A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.
D010265 Paraproteinemias A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin. Gammapathy, Monoclonal,Gammopathy, Monoclonal,Monoclonal Gammopathies,Paraimmunoglobulinemia,Paraimmunoglobulinemias,Paraproteinemia,Plasma Cell Dyscrasias,Monoclonal Gammapathies,Monoclonal Gammopathy,Cell Dyscrasia, Plasma,Dyscrasia, Plasma Cell,Monoclonal Gammapathy,Plasma Cell Dyscrasia
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D012878 Skin Neoplasms Tumors or cancer of the SKIN. Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm
D016410 Lymphoma, T-Cell, Cutaneous A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders. Granulomatous Slack Skin,T-Cell Lymphoma, Cutaneous,Cutaneous T-Cell Lymphoma,Lymphoma, T Cell, Cutaneous,Cutaneous T Cell Lymphoma,Cutaneous T-Cell Lymphomas,Lymphoma, Cutaneous T-Cell,Lymphomas, Cutaneous T-Cell,Slack Skin, Granulomatous,T Cell Lymphoma, Cutaneous,T-Cell Lymphomas, Cutaneous
D017809 Fatal Outcome Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept. Fatal Outcomes,Outcome, Fatal,Outcomes, Fatal

Related Publications

E S Miralles, and M Núñez, and P Boixeda, and R Moreno, and C Bellas, and A Ledo
December 2000, [Rinsho ketsueki] The Japanese journal of clinical hematology,
E S Miralles, and M Núñez, and P Boixeda, and R Moreno, and C Bellas, and A Ledo
March 1986, Veterinary pathology,
E S Miralles, and M Núñez, and P Boixeda, and R Moreno, and C Bellas, and A Ledo
January 1989, [Rinsho ketsueki] The Japanese journal of clinical hematology,
E S Miralles, and M Núñez, and P Boixeda, and R Moreno, and C Bellas, and A Ledo
October 1984, Clinical chemistry,
E S Miralles, and M Núñez, and P Boixeda, and R Moreno, and C Bellas, and A Ledo
March 2008, Annals of hematology,
E S Miralles, and M Núñez, and P Boixeda, and R Moreno, and C Bellas, and A Ledo
March 1979, Archives of dermatology,
E S Miralles, and M Núñez, and P Boixeda, and R Moreno, and C Bellas, and A Ledo
January 1998, Ryoikibetsu shokogun shirizu,
E S Miralles, and M Núñez, and P Boixeda, and R Moreno, and C Bellas, and A Ledo
November 1991, Zhonghua Minguo wei sheng wu ji mian yi xue za zhi = Chinese journal of microbiology and immunology,
E S Miralles, and M Núñez, and P Boixeda, and R Moreno, and C Bellas, and A Ledo
July 1984, The New England journal of medicine,
E S Miralles, and M Núñez, and P Boixeda, and R Moreno, and C Bellas, and A Ledo
May 2024, Blood,
Copied contents to your clipboard!